Joseph Caporusso, DPM
Foot & Ankle Surgery · McAllen, TXNPI 1528062213
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Organogenesis Inc. accounts for 91.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $82,424 and has fallen 98.6% since, to $1,123 in 2025. Among foot & ankle surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $571.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$263K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$21K
- Mylan Specialty L.p.$1K
- Endo USA, Inc.$837
- Biotissue Holdings Inc.$584
- Amgen$423
- plus $2K from 14 others
Across 328 payments — averaging $18,121 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$3.8M
- Tris Pharma Inc$695K
- Biotissue Holdings Inc.$496K
- Endo Pharmaceuticals Inc.$186K
- Integra Lifesciences Corporation$178K
- GSK$172K
- plus $404K from 9 others
What the payments were for
- Consulting fees$77,01827%
- Speaking & faculty fees$166,31558%
- Travel & lodging$38,72513%
- Food & beverage$7,1552%
- Entertainment$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 437 | $263,209 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 16 | $21,249 |
| Mylan Specialty L.p. | 5 | $1,399 |
| Endo USA, Inc. | 4 | $837 |
| Biotissue Holdings Inc. | 2 | $584 |
| Amgen | 8 | $423 |
| AbbVie(2 entities) | 3 | $235 |
| Smith+Nephew | 3 | $231 |
| Medline Industries LP | 2 | $182 |
| Melinta Therapeutics, LLC | 4 | $162 |
| Polarityte, Inc. | 2 | $150 |
| GRT US Holding, Inc. | 2 | $132 |
| Averitas Pharma Inc. | 1 | $117 |
| Paratek Pharmaceuticals, Inc. | 2 | $110 |
| Aroa Biosurgery Incorporated | 6 | $54 |
| Osiris Therapeutics Inc. | 2 | $42 |
| Amniox Medical, Inc. | 3 | $42 |
| Hydrofera LLC | 2 | $35 |
| Kerecis Limited | 1 | $16 |
| Sebela Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PuraPly$112,121
- Apligraf$59,808
- Dermagraft$54,462
- Puraply/Affinity/NuTech$54,462
- Affinity$49,419
- Puraply Antimicrobial$29,111
- JUBLIA$20,917
- NuShield$8,661
- PURAPLY WOUND MATRIX$1,560
- NOVACHOR$1,560
- Prokera$584
- AmnioGraft$584
- AmnioGuard$584
- KRYSTEXXA$370
- Qutenza$236
- AVYCAZ$140
- SkinTE$137
- Grafix$120
- GRAFIX PL$120
- Stravix$120
How this compares
$289,225 in reported general payments places this provider in the 95th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 38 | $34,689 |
| Ciclopirox | 651 | $23,381 |
| SantylCollagenase Clostridium Hist. | 17 | $9,780 |
| Clotrimazole | 38 | $769 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 33 | $430 |
| Doxycycline Hyclate | 17 | $328 |
| Ammonium Lactate | 14 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $21,249 | $34,68938 claims |
| Smith+NephewSantyl | $231 | $9,78017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 684 foot & ankle surgery providers in Texas.
Other foot & ankle surgery in McAllen
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
- Abdul NurudeenHouston$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.